Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Intermittent endocrine treatment.

P J Van Cangh1, B Tombal, J L Gala

  • 1Department of Urology, Cliniques Universitaires St. Luc, Brussels, Belgium. vancangh@chex.ucl.ac.be

World Journal of Urology
|August 5, 2000
PubMed
Summary

Intermittent endocrine therapy for prostate cancer delays progression and improves quality of life by reducing side effects. This cyclic approach shows promise, with further survival data pending randomized trials.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Final overall survival results from EORTC 1333/PEACE-3 trial of enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Local and locoregional prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Neuroendocrine neoplasms of head and neck, genitourinary and gynaecological systems, unknown primaries, parathyroid carcinomas and intrathyroid thymic neoplasms: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

ESMO open·2024
Same author

Validation of metastasis-free survival as a surrogate endpoint for overall survival in localized prostate cancer in the era of docetaxel for castration-resistant prostate cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2023

Area of Science:

  • Oncology
  • Endocrinology
  • Urology

Background:

  • Prostate cancer treatment often involves continuous androgen ablation, leading to side effects.
  • Intermittent endocrine therapy (IET) aims to mitigate these side effects while managing cancer progression.

Observation:

  • Experimental data and Phase II studies suggest IET is feasible.
  • Patients experience apoptotic regressions and improved quality of life, including sexual function.

Findings:

  • Recommended therapy cycles are 6-9 months, with off-therapy intervals around 50% of treatment duration.
  • The mean time to disease progression observed was 32 months.

Implications:

  • IET offers a viable strategy for improving quality of life in prostate cancer patients.
  • Ongoing randomized studies are crucial to confirm the impact of IET on prolonged survival.

Related Experiment Videos